Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Directeur du programme CAR-T (1) au sein du département d’hémato-immunologie pédiatrique de l’Hôpital Robert Debré à Paris, le Pr André Baruchel plaide pour l’invention d’un nouveau modèle de développement, production et autorisation des CAR-T et pour un changement du statut de ces thérapies géniques ex-vivo. Quels sont les problèmes que pose selon vous le modèle … 
No comment yet.
Sign up to comment
|
Scoop.it!
Precision-controlled CAR-T-cell immunotherapies could be used to tackle a range of tumour types. Via BigField GEG Tech
BigField GEG Tech's curator insight,
December 19, 2022 10:39 AM
Researchers have bolstered the power of chimeric antigen receptor (CAR)-T cancer therapies, which use genetically altered T cells to seek out tumours and mark them for destruction. Now scientists have further engineered the cells to contain switches that allow control over when and where the cells are active. This helps them to infiltrate tumours and dodge immune-suppressing defences. |
ressources sur cette page
https://www.scoop.it/topic/immunology-and-biotherapies?q=car-T